Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 14Active not recruiting 7Not yet recruiting 6Terminated 4Completed 4Withdrawn 2Approved for marketing 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 28Neoplasms 26Prostatic Neoplasms 22Colorectal Neoplasms 18Head and Neck Neoplasms 14Pancreatic Neoplasms 12Melanoma 10Lung Neoplasms 10Brain Neoplasms 10Neoplasm Metastasis 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 7Recurrence 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 7Lymphoma, Follicular 7Lymphoma 7Glioblastoma 7Leukemia, Myeloid, Acute 6Leukemia 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Ovarian Neoplasms 5Lymphoma, B-Cell 5Kidney Neoplasms 5Hematologic Neoplasms 5Sarcoma 4Liver Neoplasms 4

Interventions

pertuzumab 1Trastuzumab 1Fluorodeoxyglucose F18 1Docetaxel 1Carboplatin 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × HER2-positive Breast Cancer × 1 year × Clear all
NCT04273555 2026-02-06

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

University of Alabama at Birmingham

Phase 1/2 Withdrawn
Breast

HER2-positive Breast Cancer

NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

University of Rochester

Phase 2 Withdrawn
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡